Acquisition history Sirna Therapeutics was acquired by Merck for 1.1B in 2006, indicating strong strategic value and potential paths for licensing, collaboration, or co-development with larger pharma entities seeking RNA interference expertise.

RNAi Focus Specialization in RNA interference medicines positions Sirna as a potential partner for partnerships or contract research in gene-silencing therapies, offering opportunities for technology licensing or joint ventures with companies pursuing RNAi platforms.

Mid-scale ops Current employee footprint (11-50) and revenue range (1M–10M) suggest a lean, agile organization suitable for early-stage partnerships, outsourced research, or small-scale collaboration programs with clear scope and milestones.

Tech stack Utilization of common web and analytics tools (AdRoll, Google Tag Manager, jQuery, Bootstrap) indicates a marketing and engagement approach that can be complemented with targeted outreach, digital campaigns, and data-driven lead generation.

Market positioning Competitive landscape includes larger peers like Alnylam and Arrowhead; identify niche collaboration opportunities, early-stage co-development deals, or service-based contracts where Sirna’s RNAi expertise adds value without requiring full-scale commercialization.